Beta-band intermuscular coherence:A novel biomarker of upper motor neuron dysfunction in motor neuron disease by Fisher, Karen M. et al.
BRAIN
A JOURNAL OF NEUROLOGY
Beta-band intermuscular coherence: a novel
biomarker of upper motor neuron dysfunction
in motor neuron disease
Karen M. Fisher,1 Boubker Zaaimi,1 Timothy L. Williams,2,3 Stuart N. Baker1 and Mark R. Baker1,2,4
1 Institute of Neuroscience, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, UK
2 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK
3 Motor Neuron Disease Care Centre, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK
4 Department of Clinical Neurophysiology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK
Correspondence to: Dr M. R. Baker,
Institute of Neuroscience,
Henry Wellcome Building,
Medical School,
University of Newcastle upon Tyne,
Framlington Terrace,
Newcastle upon Tyne,
NE2 4HH, UK
E-mail: mark.baker@ncl.ac.uk
In motor neuron disease, the focus of therapy is to prevent or slow neuronal degeneration with neuroprotective pharmacological
agents; early diagnosis and treatment are thus essential. Incorporation of needle electromyographic evidence of lower motor
neuron degeneration into diagnostic criteria has undoubtedly advanced diagnosis, but even earlier diagnosis might be possible
by including tests of subclinical upper motor neuron disease. We hypothesized that beta-band (15–30 Hz) intermuscular coher-
ence could be used as an electrophysiological marker of upper motor neuron integrity in such patients. We measured inter-
muscular coherence in eight patients who conformed to established diagnostic criteria for primary lateral sclerosis and six
patients with progressive muscular atrophy, together with 16 age-matched controls. In the primary lateral sclerosis variant of
motor neuron disease, there is selective destruction of motor cortical layer V pyramidal neurons and degeneration of the
corticospinal tract, without involvement of anterior horn cells. In progressive muscular atrophy, there is selective degeneration
of anterior horn cells but a normal corticospinal tract. All patients with primary lateral sclerosis had abnormal motor-evoked
potentials as assessed using transcranial magnetic stimulation, whereas these were similar to controls in progressive muscular
atrophy. Upper and lower limb intermuscular coherence was measured during a precision grip and an ankle dorsiflexion task,
respectively. Significant beta-band coherence was observed in all control subjects and all patients with progressive muscular
atrophy tested, but not in the patients with primary lateral sclerosis. We conclude that intermuscular coherence in the 15–30 Hz
range is dependent on an intact corticospinal tract but persists in the face of selective anterior horn cell destruction. Based on
the distributions of coherence values measured from patients with primary lateral sclerosis and control subjects, we estimated
the likelihood that a given measurement reflects corticospinal tract degeneration. Therefore, intermuscular coherence has po-
tential as a quantitative test of subclinical upper motor neuron involvement in motor neuron disease.
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Introduction
Motor neuron disease is a sporadic, fatal, neurodegenerative dis-
order. It is a rare condition, with an estimated incidence of 2.4–3.9
people affected in every 100 000 (Dean et al., 1994; Alonso et al.,
2009; Logroscino et al., 2010), and includes a spectrum of con-
ditions, the most common of which is amyotrophic lateral sclerosis.
This is characterized by widespread degeneration of motor neu-
rons within the brainstem and ventral horn of the spinal cord, in
addition to destruction of layer V pyramidal neurons of the motor
cortex. Amyotrophic lateral sclerosis is typically an aggressive and
rapidly progressive form of motor neuron disease (average life
expectancy of 2.5 years from diagnosis). Diagnosis is dependent
on the presence of upper motor neuron and lower motor neuron
pathology in multiple regions (bulbar, cervical, thoracic and lum-
bosacral), according to the El Escorial criteria (Brooks, 1994), after
excluding other potentially treatable causes. The El Escorial criteria
were first revised in 1997 (Miller et al., 1999) and again in 2006
(Carvalho and Swash, 2009) to include, with increasing emphasis,
preclinical evidence on EMG of lower motor neuron disease out-
side regions identified clinically. This requires documentation of
EMG changes indicative of denervation in at least two muscles
innervated by different roots and nerves, in at least two separate
anatomical regions. As a consequence, the revised criteria have
permitted earlier diagnosis of motor neuron disease where lower
motor neuron pathology is a primary feature.
Early diagnosis is important in a disease in which the primary
strategy of treatment is to halt or slow the relentless degeneration
of motor neurons. Unfortunately, even at symptomatic presenta-
tion, when the diagnosis is often uncertain, there is already exten-
sive motor neuron degeneration. Studies suggest that these
patients lose up to 50% of motor units before a muscle becomes
symptomatically weak (Hansen and Ballantyne, 1978; Aggarwal
and Nicholson, 2002). This presents problems for clinical trials of
neuroprotective agents. First, because of extensive neuronal de-
struction, the population of salvageable motor neurons is small; at
trial recruitment, 55% of motor units remain in overtly affected
(i.e. weak and wasted) muscle and between 25% and 50% in
some clinically unaffected muscles (Hansen and Ballantyne,
1978; Aggarwal and Nicholson, 2002). Second, identifying statis-
tically significant changes in endpoints such as strength and dis-
ability will be difficult because effects will be small in patients who
may already be very weak and disabled at enrolment. Surprisingly,
despite this, early trials of riluzole in patients with amyotrophic
lateral sclerosis demonstrated small but significant benefits
(Bensimon et al., 1994; Lacomblez et al., 1996; Miller et al.,
2007). The effects of riluzole on progression and survival might
be even greater if it could be administered earlier in the disease
course, before significant cell loss had occurred.
The diagnosis of motor neuron disease is somewhat limited by
our inability to assess reliably the integrity of the corticospinal
tract, which is particularly difficult in the presence of extensive
anterior horn cell disease. Clinically, there are useful indicators of
corticospinal tract damage including the Babinski sign and
hyperreflexia; however, these may not solely reflect pathology
restricted to the corticospinal tract (Brown, 1994). Transcranial
magnetic stimulation has been assimilated into the diagnostic
criteria for primary lateral sclerosis (a pure upper motor neuron
variant of motor neuron disease) as a test of corticospinal tract
function (Pringle et al., 1992); accepted abnormalities include
small or absent motor-evoked potentials or prolonged central
motor conduction times. Magnetic stimulation has also been
used in the more common variants of motor neuron disease to
aid diagnosis, but its usefulness has been questioned (Mills, 2003),
not least because of a requirement for expensive equipment and
the necessary expertise. The triple stimulation technique has
increased the diagnostic sensitivity of magnetic stimulation in
motor neuron disease (Magistris et al., 1998, 1999) but is uncom-
fortable and time consuming. Further attempts to quantify corti-
cospinal tract integrity include methods using magnetic resonance
spectroscopy (Pohl et al., 2001; Mitsumoto et al., 2007) and MRI
tractography (Ciccarelli et al., 2006). However, these methods
require expensive MRI systems with specifications and expertise
that are also not universally available.
An alternative method to assess upper motor neuron integrity
could be to investigate the propagation of oscillatory activity.
Rhythmic activity can be recorded from the motor cortex in
both animals (Murthy and Fetz, 1996; Baker et al., 1997;
Donoghue et al., 1998) and human subjects (Salmelin and Hari,
1994; Halliday et al., 1998) in the alpha (8–12Hz) and beta
(15–30Hz) frequency bands. Coherence analysis reveals that
only beta frequency oscillations are synchronized between cortex
and contralateral EMG, suggesting that these oscillations are trans-
mitted from cortex to muscle (Conway et al., 1995; Murthy and
Fetz, 1996; Baker et al., 1997, 1999; Salenius et al., 1997;
Halliday et al., 1998; Kilner et al., 2000).
In normal subjects, beta-band coupling can also be observed
between muscles (intermuscular coherence), demonstrating a
shared cortical drive. Intermuscular coherence is maximal during
a sustained muscle contraction (Baker et al., 1997; Norton and
Gorassini, 2006) and seems to be dependent on supraspinal struc-
tures, including the corticospinal tract, because it disappears after
stroke and complete spinal cord injury (Farmer et al., 1993;
Norton et al., 2003, 2004; Hansen et al., 2005). Moreover, in
partial spinal cord injury where some corticospinal fibres may be
spared, physical therapy can increase not only functional recovery
and motor-evoked potential amplitudes but also 15–30Hz inter-
muscular coherence (Norton and Gorassini, 2006). Alpha-band
intermuscular coherence can also sometimes be observed in
healthy subjects; however, this is likely to be largely dependent
on segmental or spinal mechanisms because it persists after com-
plete spinal cord lesions (Norton et al., 2003, 2004).
The extent to which the corticospinal tract contributes to human
corticomuscular and intermuscular coherence in the 15–30Hz
range is somewhat controversial. Although some studies have
identified phase lags between cortex and muscle that might be
consistent with conduction via the fastest corticospinal axons
(Gross et al., 2000; Marsden et al., 2000; Mima et al., 2000)
and therefore corticofugal propagation of oscillations, others
have not (Conway et al., 1995). Studies in which 15–30Hz oscil-
lations have been disrupted, or reset by stimulating the corticosp-
inal tract (Jackson et al., 2002; Hansen and Nielsen, 2004), have
been presented as further evidence of a corticofugal hierarchy for
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15–30Hz oscillations (Hansen and Nielsen, 2004). However,
recent work has revealed the important contribution of afferent
feedback pathways to corticomuscular coherence (Riddle and
Baker, 2005; Baker et al., 2006) and demonstrated that activity
in the somatosensory cortex also shows corticomuscular coherence
(Brovelli et al., 2004; Witham et al., 2010, 2011).
To determine whether intermuscular coherence is a useful bio-
marker of upper motor neuron dysfunction, we must first test
whether the technique can discriminate between upper and
lower motor neuron lesions. In this article, we examine this
using two variants of motor neuron disease, which initially present
as either pure upper or lower motor neuron disorders. Progressive
muscular atrophy, which affects 5–10% of patients with motor
neuron disease, is a degenerative condition that is initially limited
to spinal motor neurons. By contrast, in primary lateral sclerosis,
there is selective degeneration of layer V pyramidal neurons (Betz
cells) within the precentral gyrus and corticospinal tract axons, but
with preservation of anterior horn cells (Pringle et al., 1992; Le
Forestier et al., 2001; Gordon et al., 2006). Although in both
primary lateral sclerosis and progressive muscular atrophy, hand
function is impaired and foot movements are slow and weak,
there is usually sufficient residual function to perform simple re-
petitive manual and pedal tasks. Therefore, these two conditions
allow us to address whether coherence reflects corticospinal tract
integrity and could be considered as a biomarker of upper motor
neuron dysfunction.
Materials and methods
Subjects
Some recordings reported in this article were made as part of routine
neurophysiological investigations in patients required for diagnostic
work-up. The remaining recordings from patients were gathered in a
dedicated research study, approved by a National Research Ethics
Service Committee. Studies in control subjects were approved by the
Research Ethics Committee of the Medical Faculty, Newcastle
University. In all cases, informed consent was obtained before inves-
tigation in accordance with the Declaration of Helsinki.
In eight patients (six males, two females; age range: 42–75 years,
mean age: 57.9 years), a diagnosis of primary lateral sclerosis had been
made after excluding other causes, (Table 1) according to previously
published diagnostic criteria (Pringle et al., 1992). Investigations
included normal structural imaging, normal motor and sensory nerve
conduction studies, normal somatosensory-evoked potentials (not per-
formed in patients with progressive muscular atrophy), normal CSF
(oligoclonal bands) and a minimum disease duration of 3 years without
either clinical or neurophysiological evidence of anterior horn cell
disease.
Six patients with a diagnosis of progressive muscular atrophy (four
males, two females; age range: 61–73 years, mean age: 66.7 years)
were also investigated (Table 2). The diagnosis of progressive muscular
atrophy is one of exclusion; patients had electrophysiological evidence
of lower motor neuron degeneration in the absence of upper motor
neuron signs, a progressive course and no structural, immunological or
known genetic explanation for their clinical presentation. Therefore,
according to El Escorial criteria (Brooks, 1994), patients with
progressive muscular atrophy are classified as suspected amyotrophic
lateral sclerosis.
Control data were obtained from 16 age-matched normal human
subjects (eight males, eight females; age range: 47–78 years, mean
age: 62.2 years), with no history of neurological abnormality.
Recordings
In the upper limb, surface EMG recordings (electrodes: Bio-logic
M0476, Natus Europe GmbH) were made from the first dorsal inter-
osseous, extensor digitorum communis and flexor digitorum superfi-
cialis muscles. To ensure that cooling did not affect coherence
measurements (Riddle and Baker, 2005), surface EMG recording was
acquired with a skin temperature of 434C (i.e. with muscle and
nerve temperature of 37C) in all subjects (according to standard
clinical practice). In the majority of cases, we recorded from the side
of the body most affected by the disease, although where patients
presented with bilateral impairment, we used the dominant hand.
In the lower limb, EMG recordings were made from extensor digi-
torum brevis, tibialis anterior and gastrocnemius-soleus. Two patients
with primary lateral sclerosis (Patients RC and JH) and one patient with
progressive muscular atrophy (Patient HR) were unable to perform this
lower limb task. Control data were pooled from other studies that
were primarily investigating hand function so that only 12/16 subjects
performed the lower limb task.
Signals were amplified (gain 500–5000, band pass 30Hz–2 kHz) and
digitized at 5-kHz sampling rate by a Power1401 interface (CED Ltd)
and Spike2 software, together with signals indicating the time of trial
onset and occurrence of auditory cues.
In addition to EMG recordings, we also measured differential EEG
from the contralateral sensorimotor cortex using electrodes placed
30mm lateral and 20mm anterior and posterior to the vertex for
upper limb recordings (Baker and Baker, 2003; Riddle and Baker,
2006; Witham et al., 2011) and placed over vertex and 20mm anter-
ior to vertex for lower limb recordings. However, we found that
significant corticomuscular (EEG–EMG) coherence in the beta-band
was not a consistent finding among our cohort of healthy subjects,
in agreement with previous studies (Ushiyama et al., 2011). As our
aim was to measure the reduction in coherence caused by disease
processes, in this article, we do not consider results from corticomus-
cular coherence further.
Motor-evoked potentials
Motor-evoked potentials were obtained using a Magstim 200 stimu-
lator (The Magstim Co Ltd) to deliver transcranial magnetic stimulation
over motor cortex. A 13-cm outside diameter circular coil was used for
obtaining upper limb motor-evoked potentials; current direction was
optimized for stimulation of each hemisphere (A side up: left hemi-
sphere; B side up: right hemisphere). Lower limb motor-evoked
potentials were elicited via a double cone coil; again, the coil was
oriented to produce the optimal current direction (posterior coil cur-
rent: left hemisphere; anterior coil current: right hemisphere). In both
cases, the coil was centred over the vertex and held in place by hand.
Stimuli were delivered at 0.2Hz.
Active motor threshold was identified in the first dorsal interosseous
muscle while subjects provided a gentle background contraction; this
was achieved by opposing index finger and thumb. Threshold was
defined as the percentage of maximum stimulator output that pro-
duced a motor-evoked potential in around half of the stimuli.
Recordings used an intensity 10% maximum stimulator output
above threshold to elicit well-formed large motor-evoked potentials
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in all muscles. In some patients, the threshold was either very high or
could not be determined; here, magnetic stimulation at the maximum
stimulator output was used. A steady background contraction was
maintained throughout the recording period.
Precision grip task
To test intermuscular coherence, subjects were asked to perform a
simple repetitive task. For the upper limb, they were required to per-
form a precision grip, guided by a length of compliant plastic tubing
(Portex; external diameter 10mm, internal diameter 8mm, 19-cm
long) attached to the index finger and thumb with micropore tape.
Subjects were instructed to oppose the two ends of the tubing, a
movement that required a minimum force of 1 N. The task followed
the pattern of a 3-s contraction, followed by a 2-s rest period; auditory
cues to instruct the subject when to grip and relax were generated by
a computer. This is an ‘auxotonic’ task (from the Greek ‘auxein’ to
increase and ‘tonos’ tension), as force varies with displacement in a
spring-like fashion. The task is similar to that used in our previous
work, although without measurement of digit displacement (Kilner
et al., 2000; Baker and Baker, 2003; Riddle et al., 2004). For lower
limb investigations, subjects were asked to dorsiflex the ankle in air;
once again, computer-generated tones cued the onset and offset of
contractions. For each task, subjects were asked to perform 100 move-
ment repetitions. If necessary, this was divided into a number of dif-
ferent recordings, separated by rests to prevent fatigue (only required
for one patient).
Animal recording
To complement the measurements made in patients, we also per-
formed motor-evoked potentials and intermuscular coherence in a
single female macaque monkey (Macaca mulatta) that had been sub-
jected 3 months previously to a unilateral lesion of the pyramidal tract
at the medulla. The lesion was made by a radiofrequency thermocoa-
gulation probe stereotaxically introduced into the pyramid while the
animal was under general anaesthesia. EMG recordings were made
using implanted electrodes (Miller et al., 1993) or surface electrodes
placed on the skin overlying muscles. Motor-evoked potentials were
recorded whilst the animal was lightly sedated with ketamine (10mg/
kg intramuscularly) and used a small figure-of-eight coil (loop diameter
25mm). Intermuscular coherence was recorded in the conscious
animal during performance of a simple task. This required the end
of a spring-loaded rod to be grasped and pulled towards the animal;
release of the rod then led to a food reward. Post hoc trials were
selected to include only those with a hold period longer than 1.64 s.
Analysis of intermuscular coherence then proceeded as for the patient
recordings, using only EMG data from the hold phase of the task. The
task was performed with both the affected and unaffected upper limb
in turn, allowing comparison of intermuscular coherence between sides
contralateral and ipsilateral to the pyramidal tract lesion.
All surgical procedures were carried out under aseptic conditions and
general anaesthesia (3%–5% sevofluorane inhalation in 100% O2
with alfentanil infusion), with a full programme of postoperative anal-
gesics [buprenorphine (Vetergesic) 10mg/kg, Reckitt and Colman
Products; carprofen (Rimadyl) 5mg/kg, Pfizer] and antibiotics (LA
Clamoxyl 15mg/kg). All animal procedures were covered by appropri-
ate licences from the UK Home Office and were approved by the
Ethical Review Committee of Newcastle University.
Analysis
Data analysis was performed using custom-written Matlab
(Mathworks Inc.) routines and followed the procedures used in our
previous publications (Baker and Baker, 2003; Riddle et al., 2004).
Analysis focused on the central 1.64-s of the 3-s hold period, as
beta frequency oscillations are greatest during periods of steady con-
traction. EMG power spectra and intermuscular coherence were calcu-
lated using two contiguous 0.82-s long sections of data from each trial
and a 4096-point Fast Fourier Transform (Baker et al., 1997). This
yielded a frequency resolution of 1.22 Hz. EMG signals were full-wave
rectified before Fourier transforms were calculated. Significance levels
were calculated using the method described in Rosenberg et al.
(1989), which takes account of the length of the recording to estimate
the expected variation in coherence under the null hypothesis that
there is no coupling between the two signals. Intermuscular coherence
was calculated between the first dorsal interosseous muscle and both
flexor digitorum superficialis and extensor digitorum communis mus-
cles in the upper limb and between extensor digitorum brevis and both
tibialis anterior and gastrocnemius-soleus in the lower limb. By confin-
ing our analysis to these muscle pairs, which are physically well sepa-
rated, we avoided a contribution of electrical cross-talk to the
measured intermuscular coherence (Kilner et al., 2002).
Intermuscular coherence values are reported in two ways. First, we
averaged spectra for a given muscle pair across all patients within a
group, providing a visual representation of the dependence of coher-
ence on frequency. Significance limits for these averaged spectra were
computed as described in Evans and Baker (2003); this method adjusts
the limits on the individual spectra to reflect the improved confidence
achieved in averaging multiple independent measures. Second,
we calculated the mean coherence across the beta frequency band
(15–30Hz) for a given muscle pair in single subjects. This allowed us
to estimate the probability distribution of mean beta-band coherence
across the population. Experimental distributions were fitted to a
log-normal curve; the appropriateness of this fit was assessed using
a Kolmogorov-Smirnov test. Using these fitted curves, we were able to
determine a likelihood ratio curve, which estimated the relative likeli-
hood that intermuscular coherence of a given value came from the
primary lateral sclerosis or healthy control groups.
As well as a magnitude, coherence analysis can yield phase values,
indicating the average phase difference between the two signals. To
measure meaningful phases, significant coherence at that frequency
must be present. Because our major finding was a lack of coherence
after corticospinal tract degeneration, we were unable to assess phase
in those patients, and coherence phase is therefore not considered
further in this article.
Results
Figure 1 shows the results of investigations in a single patient with
primary lateral sclerosis (Patient AB) followed longitudinally over a
2-year period. Patient AB presented at the age of 64 years with a
2-year history of progressive tetraparesis. This began in the lower
limbs and gradually ascended; the left arm and leg were more
severely affected than the right, and the investigations were
thus limited to this side. Patient AB had no lower motor neuron
signs and normal nerve conduction studies. During the initial in-
vestigation (Fig. 1A), motor-evoked potentials were small, delayed
and poorly formed. Intermuscular coherence in the beta-band was
present (Fig. 1C), although for first dorsal interosseous-flexor
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digitorum superficialis, it was smaller than the illustrated age-
matched control subject (black trace). The patient was reassessed
22 months later, during which time the disease had gradually pro-
gressed. There was particular deterioration in mobility as a result
of lower limb weakness, and the arms were notably weaker. At
this point, there were no motor-evoked potentials present, even
when the stimulator output was maximal (Fig. 1D). There was no
significant intermuscular coherence in any of the muscles tested
(Fig. 1F). As such, it appears that both magnetic brain stimulation
and coherence are measures that reflect the degeneration of the
corticospinal tract.
A further test of the ability of intermuscular coherence to detect
corticospinal tract damage was carried out in a macaque monkey,
which had undergone a unilateral surgical lesion of the pyramidal
tract as part of an unrelated study in our laboratory. Post-mortem,
a transverse section through the pyramids at the level of the
medulla showed the extent of the lesion, and that it was confined
to the left pyramidal tract (Fig. 2A). Motor-evoked potentials
could only be elicited in the left muscles; no motor-evoked poten-
tials were seen on the right side, which was contralateral to the
lesioned pyramid (Fig. 2B). Intermuscular coherence between
coactivated muscles on the left side was clearly above significance
at beta frequencies (Fig. 2C; grey shading). On the right side,
there was significant intermuscular coherence at lower frequen-
cies, probably reflecting a broad timescale correlation in the
timing of activation in these muscles (this was also apparent on
the left side). However, intermuscular coherence in the beta fre-
quency band was close to the significance limit.
Intermuscular coherence spectra between different muscle pairs
are shown for the patient subgroups and healthy control subjects
in Figs 3 and 4. These results have been averaged across all pa-
tients within a particular group; the significance limits shown on
Figure 1 (A–C) Results obtained from Patient AB on her first assessment in the laboratory. (A) Motor-evoked potentials are shown from
three muscles in Patient AB (grey) and an age-matched control subject (black). (B) Raw EMG records show modulation with the task;
arrows indicate trial onset. (C) Intermuscular coherence spectra. Grey boxes indicate the frequency window of interest, and significance
levels are represented by grey (Patient AB) and black (control) dashed lines. Note the higher significance level for Patient AB who
completed fewer trials (these data were not used in the average to reduce coherence bias). (D–F) As in A–C, data from the patient’s
second visit to the laboratory. EDC = extensor digitorum communis; FDI = first dorsal interosseous; FDS = flexor digitorum superficialis; IM
Coh = intermuscular coherence.
Intermuscular coherence in motor neuron disease Brain 2012: 135; 2849–2864 | 2855
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/135/9/2849/325629 by Aston U
niversity user on 30 O
ctober 2019
these graphs as dashed lines are calculated taking into account the
improvement of signal:noise ratio yielded by averaging in this way
[see Evans and Baker (2003) for details of the method]. In all
muscle pairs, both in the upper and lower limbs, average inter-
muscular coherence was below significance for patients with pri-
mary lateral sclerosis (Fig. 3). This suggests a remarkably robust
result, because even low levels of intermuscular coherence would
be detected by averaging in this way across patients. By contrast,
average coherence rose above significance for all muscle pairs
examined for the patients with progressive muscular atrophy
(Fig. 4).
Averaging coherence across patient groups provides a good
summary of the impact of a given disease process on intermuscu-
lar coherence. However, to be useful as a diagnostic measure, it is
necessary that results in individual patients are sufficiently robust
to detect an abnormality. We accordingly measured the average
intermuscular coherence over the beta-band in individual patients.
The distribution of these mean intermuscular coherence values in
different patient groups is shown as cumulative probability curves
in Fig. 5A–D. Results are shown for the four different muscle pairs.
Significant differences were found in all muscle pairs between pa-
tients with primary lateral sclerosis and control subjects (first dorsal
interosseous-flexor digitorum superficialis: P50.005; first dorsal
interosseous-extensor digitorum communis: P50.05; extensor
digitorum brevis–tibialis anterior and extensor digitorum brevis–
gastrocnemius/soleus: P50.001; t-test) but not between progres-
sive muscular atrophy patients and controls (P40.1, t-test).
Overlain on the experimental cumulative distribution plots of
Fig. 5A–D are curves derived from the normal distribution of
log-transformed coherence, with the mean and standard deviation
derived from the experimental data. In all cases, the distributions
did not significantly deviate from log-normal (P40.4,
Kolmogorov-Smirnov test). Table 3 lists the parameters of these
fitted distributions.
The fitted normal probability distributions of Fig. 5A–D have
also been used to calculate likelihood ratios (odds ratios) plotted
underneath. This allows us to read off the relative likelihood that a
given value of mean beta-band intermuscular coherence has come
from the primary lateral sclerosis or the control population. As an
example, the vertical lines on each plot mark the mean coherence
values determined from the patient previously illustrated in Fig. 1.
We see that a mean beta-band intermuscular coherence of 0.0084
in the first dorsal interosseous-flexor digitorum superficialis muscle
pair is 6.8 times more likely to come from a patient with primary
lateral sclerosis than a control subject. Corresponding ratios for the
other muscle pairs for this patient were as follows: first dorsal
interosseous-extensor digitorum communis, 3.6; extensor digi-
torum brevis–tibialis anterior, 9.9; extensor digitorum brevis–
gastrocnemius/soleus, 3.7.
Note that these likelihood ratios depend heavily on the form of
the probability density used to fit the experimental distributions. It
is in the tails of the distributions that the fit between experimental
and normal curves is likely to be most divergent; accordingly, like-
lihood ratio curves have only been shown over the range of mean
beta-band intermuscular coherence values encountered in our ex-
perimental data set.
The likelihood ratio curves of Fig. 5A–D clearly could provide
useful information, but even at their peak (around 10:1), the ratios
are not high enough to yield a definitive diagnosis. However, be-
cause the measurements from each muscle pair are statistically
independent, a combined likelihood ratio can be computed by
multiplying together the values from the different muscle pairs.
In the illustrated patient with primary lateral sclerosis, taking the
product of the ratios from all four muscles, we would conclude
that this patient was 880 times more likely to have a degenerated
than normal corticospinal tract.
Prospective case study
Figure 6 summarizes the results obtained from a separate patient
studied prospectively after presentation to the motor neuron dis-
ease clinic. Patient AP is a 30-year-old male with a 2-year history
of progressive weakness and muscle wasting in the lower limbs.
He initially presented with a unilateral foot drop; symptoms then
Figure 2 (A) Transverse section through the pyramids at the
level of the medulla showing the extent of the pyramidal tract
lesion in monkey M. (B) Motor-evoked potentials obtained from
left (black) and right (grey) first dorsal interosseous muscles 3
months post lesion to the left pyramidal tract. (C) Intermuscular
coherence plots calculated from EMG data collected during a
steady hold task. Dashed line indicates significance level. BIC = ;
FDI = first dorsal interosseous; L = left; R = right.
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progressed in an ascending and asymmetric manner predominantly
affecting the left leg. There was no upper limb involvement and
no upper motor neuron signs at this stage. Initial EMG studies
revealed neurogenic changes that were confined to the lower
limbs (concentric needle EMG demonstrated unstable polyphasic
motor units, positive sharp waves and fibrillation potentials in right
and left tibialis anterior, medial gastrocnemius and vastus lateralis
and right abductor hallucis) in the presence of normal sensory
nerve action potentials and sensory nerve conduction velocities.
This was felt to be consistent with a lumbo-sacral
polyradiculopathy. A follow-up study was completed 10 months
later because there was a clear progression in symptoms; the
lower limb muscles became progressively more wasted and
the patient became aware of fasciculations in the lower limbs.
The second neurophysiological examination revealed severe
active neurogenic changes in the lower limbs combined with
mild changes in the upper limbs (i.e. no spontaneous activity or
unstable motor units). These were thought to be indicative of
diffuse anterior horn cell disease. However, because clinical evi-
dence of upper motor neuron involvement was restricted to the
Figure 3 Population averages are shown for intermuscular coherence in primary lateral sclerosis patients (grey) and age-matched controls
(black). Upper limb results are shown in A–B [eight patients (15 muscles) & 16 controls (32 muscles)] and lower limb results are shown in
C–D [six patients (12 muscles) & 12 controls (24 muscles)]. Grey shaded boxes indicate the frequency window of interest. EDB = extensor
digitorum brevis; EDC = extensor digitorum communis; FDI = first dorsal interosseous; FDS = flexor digitorum superficialis;
GS = gastrocnemius/soleus; IM = intermuscular; PLS = primary lateral sclerosis; TA = tibialis anterior.
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lower limbs, the patient only met diagnostic criteria for clinically
possible motor neuron disease. At this stage, no significant
beta-band intermuscular coherence was found in either the
lower or upper limb (Fig. 6B). Subsequently, genetic tests revealed
this patient to have a point mutation at c341T4C in the SOD1
(superoxide dismutase) gene on chromosome 21q. This mutation
has been shown to be linked to familial amyotrophic lateral scler-
osis (Rosen et al., 1993). Based on the curves of Fig. 5A–D, the
combined likelihood ratio for this patient having a degenerated
versus a normal corticospinal tract across all muscle pairs was
calculated as 281:1 (first dorsal interosseous-flexor digitorum
superficialis: 7.95; first dorsal interosseous-extensor digitorum
communis: 5.9; extensor digitorum brevis–tibialis anterior: 0.54;
extensor digitorum brevis–gastrocnemius/soleus: 11.04).
Detection of abnormal intermuscular coherence was completed
6 months before the positive genetic test for Patient AP. It is
likely that these changes in intermuscular coherence actually
occurred earlier in the disease course but we were unable to
Figure 4 Population averages are shown for intermuscular coherence in patients with progressive muscular atrophy (grey) and
age-matched control subjects (black). Upper limb results are shown in (A) (six patients, 10muscles) and (B) (16 control subjects, 32muscles),
and lower limb results are shown in (C and D) [six patients and 13 control subjects (24 muscles)]. Grey shaded boxes indicate the frequency
window of interest. EDB = extensor digitorum brevis; EDC = extensor digitorum communis; FDI = first dorsal interosseous; FDS = flexor
digitorum superficialis; GS = gastrocnemius/soleus; IM = intermuscular; PMA = progressive muscular atrophy; TA = tibialis anterior.
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confirm this because the patient was only referred for motor-
evoked potentials or intermuscular coherence once there was a
strong clinical suspicion of motor neuron disease.
Since the genetic diagnosis, Patient AP’s condition has pro-
gressed resulting in wasting and weakness in both hands. He
now relies on two crutches for day-to-day ambulation with inter-
mittent use of a wheelchair. This progressive disability has
prompted his recent move into a specially adapted bungalow.
Despite the clear progression in symptoms, Patient AP would
remain classified as ‘clinically possible’ motor neuron disease on
Figure 5 Cumulative distribution plots are shown for intermuscular coherence between (A) first dorsal interosseous-flexor digitorum
superficialis (FDI-FDS); (B) first dorsal interosseous-extensor digitorum communis (FDI-EDC); (C) extensor digitorum brevis–tibialis anterior
(EDB-TA); and (D) extensor digitorum brevis–gastrocnemius/soleus (EDB-GS). Coherence is plotted on a logarithmic scale. In each case,
the individual histograms of coherence values are shown for patients with primary lateral sclerosis (blue), progressive muscular atrophy
(red) and control subjects (black) with the log-normal curve fit (dotted line) superimposed. The odds ratio curve is also displayed for each
muscle pair. MND = motor neuron disease.
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standard criteria if the positive genetic findings were disregarded.
The addition of intermuscular coherence to the Awaji criteria
would have permitted a classification of ‘clinically probable’
motor neuron disease, the qualifying criterion for riluzole therapy
within the UK National Health Service and the typical threshold for
entry to most therapeutic trials, and would have advanced the
diagnosis in this patient by almost 2 years (Fig. 6A).
Discussion
Beta-band oscillations in muscle activity are thought to occur as a
result of a common cortical drive from the corticospinal tract.
Various hypotheses on their function suggest that they could be
used for sensorimotor processing or calibration (Baker, 2007) or
promote stable motor output (Pogosyan et al., 2009). These os-
cillations and the coupling between them disappear after stroke
and complete spinal cord injury in patients (Farmer et al., 1993;
Norton et al., 2003, 2004; Hansen et al., 2005) and following
unilateral lesions of the corticospinal tract (at the level of the
spinal cord) in monkeys (Nishimura et al., 2009; Nishimura and
Isa, 2011). Beta-band oscillations have also been demonstrated to
reflect recovery of function in patients with partial spinal cord
injury (Norton and Gorassini, 2006). In support of these findings,
we observed no significant beta-band intermuscular coherence in
a monkey with a focal lesion of the corticospinal tract, or in pa-
tients with primary lateral sclerosis. Histological evidence from
post-mortem studies has confirmed that neuronal attrition is lim-
ited to the Betz cells within layer V of primary motor cortex in
primary lateral sclerosis (Pringle et al., 1992). This would suggest
that it is specifically the large diameter fastest conducting corti-
cospinal axons that are fundamental to beta-band intermuscular
coherence in man.
Roopun et al. (2006) showed evidence of beta oscillations
(20–30Hz) generated in layer V pyramidal cells in cortical slices.
These oscillations were not dependent on synaptic input but were
abolished by reducing gap junction conductance between the pyr-
amidal cells within layer V. Jackson et al. (2002) demonstrated
that the phase of beta oscillations could be reset by stimulation
of the pyramidal tract in monkeys. Baker et al. (2003) showed that
motor cortical oscillations were encoded by pyramidal tract neu-
rons. These reports all support the suggestion that pyramidal tract
neurons are involved in the generation of beta oscillations and
their propagation to the periphery.
Beta-band intermuscular coherence was observed in all control
subjects tested, including age-matched healthy subjects and pa-
tients with progressive muscular atrophy. We conclude that inter-
muscular coherence in the 15–30-Hz range is dependent on an
intact corticospinal tract, whereas it is not substantially altered by
loss of anterior horn cells. We therefore propose that assessment
of intermuscular coherence could provide additional diagnostic in-
formation about involvement of the corticospinal tract in motor
neuron disease. As illustrated by the case study, intermuscular
coherence can be absent before clinical criteria for motor neuron
disease are met (Fig. 6). The additional information provided by
intermuscular coherence studies might therefore also allow the
definitive diagnosis of motor neuron disease to be made earlier
in the course of the disease, with obvious implications for therapy
and recruitment to clinical trials. Previous studies have shown that
the presence of corticomuscular coherence in a given healthy in-
dividual is repeatable across different measurement sessions (Pohja
et al., 2005; Witham et al., 2011), and in our experience, inter-
muscular coherence is even more reliable. This should therefore be
a robust and reliable test.
In an earlier monkey study, animals recovering from a corticosp-
inal tract lesion in the high cervical spinal cord lost beta-band
intermuscular coherence, but progressively developed intermuscu-
lar coherence at higher (gamma-band) frequencies (Nishimura
et al., 2009). Nishimura et al. (2009) proposed that gamma-band
intermuscular coherence reflected a subcortical network involved
in functional recovery after the lesion. The lack of such
gamma-band coupling in our patients with primary lateral sclerosis
(Fig. 3) suggests that this compensation process—whatever its
origin—does not occur during the progressive loss of corticospinal
axons seen in motor neuron disease.
Patient characteristics
Although the diagnosis of clinically proven primary lateral sclerosis
can only be made at post-mortem, all the patients included in this
study fulfilled the criteria for clinically definite primary lateral scler-
osis (Pringle et al., 1992). Recently an upper motor neuron dom-
inant amyotrophic lateral sclerosis variant has been recognized
(Gordon et al., 2006). Although this group have a better prognosis
than most patients with amyotrophic lateral sclerosis (average life
expectancy 6–7 years from diagnosis), their prognosis is signifi-
cantly worse than that of patients with primary lateral sclerosis.
Upper motor neuron dominant patients develop evidence of active
denervation on EMG 3–4 years after presenting with upper motor
neuron signs, and therefore, it has been suggested that the
Table 3 Parameters of log-normal fits to experimental
distributions of beta-band intermuscular coherence
Muscle pair Control PLS PMA
FDI-FDS
Mean 1.459 2.121 1.663
SD 0.522 0.146 0.291
FDI-EDC
Mean 1.728 2.138 1.582
SD 0.441 0.118 0.424
EDB-TA
Mean 1.504 2.311 1.747
SD 0.400 0.124 0.381
EDB-GS
Mean 1.500 2.243 1.830
SD 0.415 0.108 0.409
Coherence values were first averaged over the 15–30Hz band and then trans-
formed by taking log10. The table lists the mean and standard deviation of these
log-transformed beta-band intermuscular coherence values, which were used to
generate the curves overlain on the experimental distributions of Fig. 5.
EDC = extensor digitorum communis; FDI = first dorsal interosseous; FDS = flexor
digitorum superficialis; GS = gastrocnemius/soleus; PLS = primary lateral sclerosis;
PMA = progressive muscular atrophy; TA = tibialis anterior.
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Figure 6 Prospective patient data from a 30-year-old male patient with suspected anterior horn cell disease. (A) Gantt chart showing
timeline of diagnosis according to available consensus criteria (not considering coherence or genetic tests) and clinical tests. (B) Intermuscular
coherence spectra for each muscle pair are illustrated. The shaded box indicates the frequency window of interest. Underneath each
frequency spectrum is the corresponding odds ratio plot from Fig. 5. Dashed line shows log coherence values found in the left upper and
lower limbs for Patient AP. EDB = extensor digitorum brevis; EDC = extensor digitorum communis; EMG/NCS = electromyogram/nerve
conduction studies; FDI = first dorsal interosseous; FDS = flexor digitorum superficialis; GS = gastrocnemius/soleus; IMC = intermuscular
coherence; MEPs = motor-evoked potentials; MND = motor neuron disease; TA = tibialis anterior.
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diagnostic criteria for primary lateral sclerosis should be modified
to stipulate that EMGs must be normal 4 years (rather than 3
years) after onset (Gordon et al., 2006). Although the diagnosis
of primary lateral sclerosis in one patient could potentially be
revised to upper motor neuron dominant amyotrophic lateral scler-
osis on this criterion, this change would not affect our findings for
two important reasons. First, the predominant histological picture
in upper motor neuron dominant amyotrophic lateral sclerosis,
particularly in the first 3 to 4 years, is one of corticospinal tract
destruction. Second, 15–30Hz intermuscular coherence persists
despite the widespread anterior horn cell destruction observed in
patients with progressive muscular atrophy.
Four patients with primary lateral sclerosis in our study were
taking the neuroprotective agent riluzole (Table 1), which has a
number of potentially confounding pharmacological actions.
Riluzole blocks non-inactivating persistent-inward sodium current
(Urbani and Belluzzi, 2000), activates TREK-1 and TRAAK leak
potassium conductances (Duprat et al., 2000) and blocks protein
kinase C (Noh et al., 2000), thereby reducing glutamate release
(Wang et al., 2004), increasing glutamate reuptake (Fumagalli
et al., 2008) and enhancing the postsynaptic effects of
GABA(A)-mediated inhibition (He et al., 2004). Reduced extracel-
lular glutamate concentrations are unlikely to affect beta fre-
quency oscillations in frontal cortex (Roopun et al., 2006),
whereas enhanced GABA(A) transmission may modulate oscilla-
tions in 8–12 and 15–30Hz ranges (Baker and Baker, 2003).
Although by blocking protein kinase C riluzole could theoretically
inhibit intracellular calcium oscillations (Kim et al., 2005), there is
no evidence linking 50.01Hz intracellular calcium fluctuations and
8–30Hz cortical oscillations. Reassuringly, in our study, there was
no significant difference between the results obtained from the
four patients with primary lateral sclerosis who were taking riluzole
and the four who were not. Moreover, the patients with progres-
sive muscular atrophy who were taking riluzole (Table 2) all had
normal intermuscular coherence.
Corticospinal tract degeneration has been demonstrated in a
small group of patients with progressive muscular atrophy at
post-mortem (Ince et al., 2003). It is impossible to determine at
what stage of the disease these features manifest, although a
recent tract imaging study showed there is no difference in corti-
cospinal tract integrity between patients with progressive muscular
atrophy and control subjects (Cosottini et al., 2005). Whilst we
cannot prove that there was no upper motor neuron involvement
in any of our patients with progressive muscular atrophy, they all
had coherence in the beta range, which suggests that this was not
a primary feature of their disease.
Clinical applications of coherence
analysis
Recently it has become clear that sensory afferents also play an
important role in 15–30Hz corticomuscular coherence (Baker
et al., 2006; Riddle and Baker, 2006; Witham et al., 2010,
2011) and intermuscular coherence (Pohja and Salenius, 2003;
Kilner et al., 2004). There are also reports that central sensory
pathways can be implicated in motor neuron disease (Hamada
et al., 2007; Mochizuki et al., 2011). Therefore, any diagnostic
inference regarding corticospinal tract function using intermuscular
coherence can only be made in the presence of normal somato-
sensory-evoked potentials, sensory nerve action potentials and
sensory nerve conduction velocities. Such tests were performed
in our patients with primary lateral sclerosis, yielding normal find-
ings. By contrast, where normal intermuscular coherence is de-
tected, corticospinal tract degeneration is unlikely. In such cases,
it is unnecessary also to test electrophysiologically for intact sen-
sory pathways; following this logic, somatosensory-evoked poten-
tials were not measured in our patients with progressive muscular
atrophy.
Beta-band intermuscular or corticomuscular coherence also
seems to require functioning basal ganglia circuitry (Grosse
et al., 2002) because in Parkinson’s disease it is diminished
when treatment is withdrawn and restored to levels comparable
to those seen in healthy age-matched control subjects by stimu-
lation of the subthalamic nucleus or administration of L-DOPA
(McAuley et al., 2001; McKeown et al., 2006). Although
Parkinson’s disease and motor neuron disease occur together
very infrequently (Williams et al., 1995), caution should be exer-
cised when interpreting results if parkinsonian features are present.
This study was designed to provide some clarification of the
origin of coherence and its potential value as a diagnostic indica-
tor. Our results demonstrate that intermuscular coherence is a
simple, inexpensive and accessible measure of corticospinal tract
integrity. All that is required are facilities for EMG recording (avail-
able in all Clinical Neurophysiology departments) and the requisite
analysis software. A large prospective clinical trial is clearly war-
ranted to further examine the potential impact of this technique
on diagnosis.
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